Summary
Synopsys Inc. (SNPS) reported a strong fiscal year ending October 31, 2013, with revenue increasing by 12% to $1.96 billion and net income growing by 36% to $247.8 million. This growth was driven by a combination of organic expansion and strategic acquisitions made in the prior year, particularly in the IP and system-level solutions sectors. The company's business model, which relies heavily on time-based revenue (approximately 90% of total revenue), provides a degree of revenue predictability, as a substantial portion of revenue is recognized over the contract term. The company demonstrated solid financial health with robust cash flow generation and a strengthening balance sheet, ending the year with $1.02 billion in cash and cash equivalents. Synopsys continued to invest significantly in research and development ($669.2 million), underscoring its commitment to innovation and maintaining its competitive edge in the dynamic electronic design automation (EDA) market. The company also actively managed its capital structure through stock repurchases and prudent debt management. Key risks highlighted include continued global economic uncertainty impacting customer spending, intense competition, and the need for successful integration of acquired businesses. However, Synopsys's diversified product portfolio, strong customer relationships, and focus on advanced technology position it well for continued growth in the semiconductor and electronics industries.
Financial Highlights
54 data points| Revenue | $1.96B |
| Cost of Revenue | $453.55M |
| Gross Profit | $1.51B |
| R&D Expenses | $669.20M |
| Operating Expenses | $1.26B |
| Operating Income | $246.49M |
| Interest Expense | $1.70M |
| Net Income | $247.80M |
| EPS (Basic) | $1.62 |
| EPS (Diluted) | $1.58 |
| Shares Outstanding (Basic) | 153.32M |
| Shares Outstanding (Diluted) | 156.60M |
Key Highlights
- 1Total revenue increased 12% to $1.96 billion for fiscal year 2013.
- 2Net income grew significantly by 36% to $247.8 million.
- 3The company's business model emphasizes time-based revenue (90%), providing predictable revenue streams.
- 4Research and development expenses increased to $669.2 million, reflecting continued investment in innovation.
- 5Synopsys maintained a strong liquidity position with $1.02 billion in cash and cash equivalents at year-end.
- 6The company actively repurchased stock, with $127.4 million available under its program at year-end.
- 7Significant acquisitions in the prior year contributed to revenue growth and portfolio expansion.